To explore the integration of AI-driven tools with AMH and inhibin B biomarkers for improved clinical decision-making and enhanced patient outcomes in reproductive medicine.
Key Findings:
AMH is a stable marker for ovarian reserve, while inhibin B provides dynamic feedback on follicular activity, with AI tools enhancing predictive accuracy in fertility assessments.
AI tools can enhance the predictive accuracy of fertility assessments and treatment protocols, leading to more tailored patient care.
Emerging technologies could broaden the application of these biomarkers beyond assisted reproduction, potentially transforming reproductive health management.
Interpretation:
The integration of AMH and inhibin B with AI can lead to more personalized and proactive reproductive healthcare, addressing patient concerns about fertility and ovarian function, and improving clinical outcomes.
Limitations:
Inhibin B has been historically underutilized due to variability and lack of standardized assays, highlighting the need for improved assay development.
Certain ovarian conditions can distort AMH measurements, affecting its reliability, necessitating further research to refine measurement techniques.
Conclusion:
AI-driven approaches in reproductive medicine can significantly improve individualized care and shift the focus from reactive to proactive health management, underscoring the importance of continued research in this evolving field.
